Eso Pediatric Obesity Pharmacotherapy Discontinue

---
name: eso-pediatric-obesity-pharmacotherapy-discontinue
description: Determines when to discontinue obesity pharmacotherapy due to lack of efficacy. Trigger phrases include “<4% BMI/BMI z score reduction after 12 weeks at full dosage” or “insufficient weight loss on antiobesity medication.”
---

# Determine when to discontinue obesity pharmacotherapy due to lack of efficacy

## STEP 1 — Gather Information
Collect baseline BMI or BMI z score, current weight and height, medication name and dose, duration of therapy at full dosage, and adherence status. Ensure measurements are taken using the same technique and equipment as baseline.

## STEP 2 — Rule In / Rule Out
Confirm the patient has received the medication at the prescribed full dosage for at least 12 consecutive weeks. If duration is <12 weeks or dosage is subtherapeutic, continue medication and reassess after adequate exposure.

## STEP 3 — Classify or Stratify
Calculate percent change: ((baseline BMI/BMI z score – current BMI/BMI z score) / baseline BMI/BMI z score) × 100. If reduction is ≥4%, classify as adequate response; if reduction is <4%, classify as inadequate response.

## STEP 4 — Decide
For inadequate response (<4% response, discontinue the medication and initiate a reevaluation of the patient’s obesity management plan, including intensification of lifestyle intervention, assessment for contributing factors, and consideration of alternative therapies or referral for bariatric surgery if criteria are met.

## Clinical Guardrails / Mimics / Pitfalls
Do not discontinue based on short-term weight fluctuations or measurement error; verify adherence before labeling as non‑response. Avoid stopping medication in patients with significant obesity‑related comorbidities (e.g., hypertension, T2DM) that may improve independent of weight loss. Do not discontinue before 12 weeks of full‑dose therapy. Ensure lifestyle modification has been optimized prior to attributing lack of efficacy to the drug.

## Concrete Clinical Example
A 14‑year‑old girl started on orlistat 120 mg TID with a baseline BMI z score of 2.6. After 12 weeks at full dose, her BMI z score is 2.55, a reduction of (2.6‑2.55)/2.6 × 100 = 1.9%. Because this is <4%, the medication is discontinued and her lifestyle program is intensified with dietary counseling and increased physical activity.

**Source:** Pediatric Obesity Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2017, DOI:10.1210/jc.2016-2573
> **TODO:** consider adding scripts/calc.py for the eso-pediatric-obesity-pharmacotherapy-discontinue calculator